Tcg Crossover Gp Ii, Llc Purchases 35,433 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc acquired 35,433 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average price of $24.88 per share, for a total transaction of $881,573.04. Following the completion of the transaction, the insider owned 675,018 shares in the company, valued at $16,794,447.84. The trade was a 5.54% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Monday, March 16th, Tcg Crossover Gp Ii, Llc acquired 1,190 shares of Surrozen stock. The stock was purchased at an average cost of $24.99 per share, for a total transaction of $29,738.10.
• On Thursday, March 12th, Tcg Crossover Gp Ii, Llc bought 12,374 shares of Surrozen stock. The stock was purchased at an average price of $24.99 per share, with a total value of $309,226.26.
• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc bought 1,093 shares of Surrozen stock. The stock was purchased at an average cost of $23.86 per share, for a total transaction of $26,078.98.
• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc bought 17,763 shares of Surrozen stock. The stock was purchased at an average cost of $23.57 per share, for a total transaction of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc purchased 4,355 shares of Surrozen stock. The shares were purchased at an average price of $21.94 per share, for a total transaction of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc purchased 731 shares of Surrozen stock. The shares were purchased at an average cost of $21.38 per share, with a total value of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The stock was purchased at an average price of $21.39 per share, with a total value of $91,356.69.

Surrozen Trading Up 0.4%

Shares of SRZN opened at $25.60 on Wednesday. The stock’s 50 day moving average is $23.58 and its two-hundred day moving average is $18.29. Surrozen, Inc. has a twelve month low of $5.90 and a twelve month high of $29.59. The firm has a market capitalization of $219.39 million, a PE ratio of -1.15 and a beta of 0.53.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. Finally, Cantor Fitzgerald started coverage on shares of Surrozen in a research report on Thursday, February 19th. They set an “overweight” rating and a $40.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.00.

Institutional Trading of Surrozen

A number of institutional investors and hedge funds have recently modified their holdings of SRZN. Braidwell LP acquired a new position in shares of Surrozen in the 2nd quarter valued at about $1,252,000. Stempoint Capital LP lifted its holdings in Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after acquiring an additional 445,713 shares during the last quarter. Stonepine Capital Management LLC lifted its holdings in Surrozen by 7.1% in the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after acquiring an additional 20,247 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in Surrozen in the fourth quarter valued at approximately $414,000. Finally, Quadrature Capital Ltd acquired a new position in Surrozen in the fourth quarter valued at approximately $335,000. 66.57% of the stock is owned by institutional investors and hedge funds.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.